AGENT FOR PREVENTING OR TREATING CYTOMEGALOVIRUS RETINITIS

摘要

PURPOSE: To obtain a cytomegalovirus(CMV) retinitis-preventing or treating agent little in side effects and high in safety. ;CONSTITUTION: The CMV retinitis-preventing or treating agent contains an anti-CMV human monoclonal antibody recognizing the envelope glycoprotein of the CMV and neutralizing the CMV. The anti-CMV human monoclonal antibody includes a human monoclonal antibody obtained by a hybridoma method using human antibody-producing cells and mouse myeloma cells subjected to an immunosensitization treatment using the envelop glycoprotein of CMV or by a EB virus-using transformation method. The anti-CMV human monoclonal antibody preferably recognizes a CMV envelope glycoprotein-B comprising the composite material of subunits having mol.wts. of 130000 dalton and 55000 dalton, and is preferably a human monoclonal antibody, regavirmab, produced by a hybridoma C23 (described in the patent specification of WO87/3602).;COPYRIGHT: (C)1996,JPO